Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Animal & Veterinary

Arthritis Drug for Horses and Dogs Scheduled to Return to Market

August 5, 2013

FDA’s Center for Veterinary Medicine (CVM) has recently received phone calls and emails from consumers who were unable to obtain Adequan IM and IA (polysulfated glycosaminoglycan), and Adequan Canine, an FDA-approved drug for the control of signs associated with non-infectious degenerative and/or traumatic lameness in horses and canines.

In response to these consumer inquiries, FDA contacted Luitpold Pharmaceuticals, Inc., the manufacturer of Adequan, and learned that the product will be available again beginning later this month (August, 2013).

For more information about this unanticipated shortage, consumers can visit the following link: www.adequan.comdisclaimer icon, the company’s webpage dedicated to Adequan. Or, call Luitpold Animal Health Customer Service Department at 1-800-458-0163.

Contact FDA

240-276-9115 FAX
Issued by: FDA, Center for Veterinary Medicine

7519 Standish Place, HFV-1

Rockville, MD 20855

Page Last Updated: 01/05/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English